EX-99.1 2 tm255146d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Contact: Kathleen Nemeth Omnicell, Inc. Senior Vice President, Investor Relations 4220 North Freeway 650-435-3318 Fort Worth, TX 76137 Kathleen. Nemeth@Omnicell.com Omnicell Announces Fiscal Year and Fourth Quarter 2024 Results Omnicell delivers strong fourth quarter financial results Results exceed previously issued full year guidance for bookings, total revenues, and non-GAAP EBITDA FORT WORTH, Texas. -- February 6, 2025 -- Omnicell, Inc. (NASDAQ:OMCL) (“Omnicell,” “we,” “our,” “us,” “management,” or the “Company”), a leader in transforming the pharmacy and nursing care delivery model, today announced results for its fiscal year and fourth quarter ended December 31, 2024. “We delivered solid financial results for the fourth quarter of 2024, including returning to year-over-year revenue growth. We are pleased with the improved execution of the business throughout 2024, including strong free cash flows achieved in the year,” stated Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “As we progress thro…
Open exhibit ↗Current Report · Items 2.02, 9.01 · 8-K
Omnicell, Inc.
OMCLNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 6, 2025, Omnicell, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.…
Company context
Since 1992, Omnicell has been committed to delivering innovative, outcomes-centric pharmacy and nursing solutions for all settings of care. As an intelligent medication management technology company, Omnicell empowers autonomous medication management by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that improve efficiency and enhance patient safety for healthcare facilities worldwide. Learn more at omnicell.com.
Current securities
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Filed exhibits (2)
EX-99.2 3 tm255146d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Investor Presentation February 6, 2025 This presentation contains “forward - looking statements” within the meaning of federal securities laws. These forward - looking sta tements include statements with respect to 2025 guidance, strategic and growth opportunities, other expectations and other non - historical information. Without limiting the foregoing, statements including the words “expect,” “intend,” “may,” “will,” “should,” “would,” “could,” “p lan,” “potential,” “anticipate,” “believe,” “forecast,” “guidance,” “outlook,” “goals,” “target,” “estimate,” “seek,” “predict,” “project,” and similar expressions are intended to i den tify forward - looking statements. Forward - looking statements are subject to the occurrence of many events outside Omnicell’s control and are subject to various risks and uncertainties, including those described below. Among other t hin gs, there can be no assurance that Omnicell’s actual results will not differ, perhaps substantially, from the targets and expectations contained in this presentation. Such statements also include, but are not limited to, Omnicell’s projected product booking…
Open exhibit ↗